Some AMPs fail to reach the last clinical trials, such as (i) frulimicin B, which was terminated after phase I clinical trial due to unfavorable pharmacokinetics [44] and (ii) murepavadin, which was eliminated after a phase III clinical trial since it causes acute kidney injuries [44]. The gene discussed is ADSL; the disease is acute kidney injury.